login
  Password reminder

Subscribe Edit your account | View your account

Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 



a b c d e f g h i j k l m n
o p q r s t u v w x y z


1 - 10 of 50   Items
MicroThermX microwave ablation system at CIRSE

MicroThermX microwave ablation system at CIRSE

Tuesday, 20 Sep 2011
The MicroThermX microwave ablation system (BSD Medical) was featured at BSD’s exhibition booth at the international meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), which was held in Munich, Germany, (10-14 September 2011). MicroThermX microwave ablation system at CIRSE
Positive phase II trial results from the neuroendocrine tumor cohort (mNET) of Delcath’s chemosaturation system

Positive phase II trial results from the neuroendocrine tumor cohort (mNET) of Delcath’s chemosaturation system

Monday, 19 Sep 2011
Overall hepatic response rate with chemosaturation treatment among patients was 70%. On the other hand, 30.4 months was the median overall survival in all patients. Positive phase II trial results from the neuroendocrine tumor cohort (mNET) of Delcath’s chemosaturation system

Hepatic chemosaturation—an emerging therapy in interventional oncology

Tuesday, 22 Feb 2011
Hepatic chemosaturation is a minimally invasive technique which delivers high doses of chemotherapy into the liver to more effectively battle tumours, while limiting toxicity to the rest of the body, making it safer than intrahepatic artery perfusion. Hepatic chemosaturation—an emerging therapy in interventional oncology

Radioembolisation prolongs life for inoperable HCC patients

Monday, 12 Jul 2010
More than three-fourths of hepatocellular carcinoma patients are not surgical candidates and radioembolisation with intra-arterial yttrium-90 extends patient survival. Radioembolisation prolongs life for inoperable HCC patients

Direct injection of gold nanoparticles into tumours could be a new treatment for pancreatic cancer

Monday, 12 Jul 2010
A radical new approach to the treatment of the disease, Reed A Omary claims. Direct injection of gold nanoparticles into tumours could be a new treatment for pancreatic cancer
North American Scientific signs definitive agreement

North American Scientific signs definitive agreement

Tuesday, 25 Sep 2007
Nomos Radiation Oncology business sold: September 2007 North American Scientific signs definitive agreement
CMS selected to provide treatment for New Proton Therapy Center

CMS selected to provide treatment for New Proton Therapy Center

Tuesday, 25 Sep 2007
CMS has been selected by ProCure Treatment Centers: September 2007 CMS selected to provide treatment for New Proton Therapy Center
Visualase announces successful treatment of brain metastases

Visualase announces successful treatment of brain metastases

Tuesday, 25 Sep 2007
completed treatment of the first six patients: September 2007 Visualase announces successful treatment of brain metastases
Newest Isotope used in brachytherapy for prostate cancer

Newest Isotope used in brachytherapy for prostate cancer

Tuesday, 25 Sep 2007
American Association of Physicists in Medicine conference: September 2007 Newest Isotope used in brachytherapy for prostate cancer
CMS collaborates with Still River Systems

CMS collaborates with Still River Systems

Tuesday, 25 Sep 2007
CMS to provide treatment planning support: September 2007 CMS collaborates with Still River Systems
Found: 50   Displaying: 1-10
Results: 1 2 3 4 5 Next Go to:
Related Section
Oncology Useful Links

Latest News




Monday, 31 Mar 2014

Features





Profiles





Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions